Fluoroestradiol
As of the edition of 20 October 2026, Fluoroestradiol is a small molecule: marketed, first approved in 2016 (FR); acts on ESR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Cerianna
- First approved
- 21 July 2016 (FR)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- GE Healthcare
- Registered trials
- 20, 7 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Fluoroestradiol.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ESR1 | Estrogen receptor | P03372 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 2 | 0 | 4 |
| Phase 1 | 3 | 1 | 1 | 1 |
| Phase 2 | 9 | 2 | 5 | 2 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 20 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GE Healthcare | Acquired holder and Lead sponsor of trials | 2022 to now |